Micro Emerging Active

JNJ ICOTYDE psoriasis trial results

Score
0,2
Vélocité
▲ 0,0
Articles
1
Sources
1

Résumé

An article belongs to this narrative if it covers Johnson & Johnson's ICOTYDE (icotrokinra) Phase 3 trial results for treating moderate-to-severe plaque psoriasis.

Articles Liés

Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In Plaque Psoriasis

Nasdaq · Mar 28, 2026
Mixed

Sources

Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In … Nasdaq

Chronologie

Dernière mise à jour Mar 28, 2026